Literature DB >> 21426023

Examining the basis of isoniazid tolerance in nonreplicating Mycobacterium tuberculosis using transcriptional profiling.

Griselda Tudó1, Ken Laing, Denis A Mitchison, Philip D Butcher, Simon J Waddell.   

Abstract

BACKGROUND: Understanding how growth state influences Mycobacterium tuberculosis responses to antibiotic exposure provides a window into drug action during patient chemotherapy. In this article, we describe the transcriptional programs mediated by isoniazid (INH) during the transition from log-phase to nonreplicating bacilli, from INH-sensitive to INH-tolerant bacilli respectively, using the Wayne model.
RESULTS: INH treatment did not elicit a transcriptional response from nonreplicating bacteria under microarophilic conditions (NRP2), unlike the induction of a robust and well-characterized INH signature in log-phase bacilli.
CONCLUSION: The differential regulation (between drug-free NRP2 and log-phase bacilli) of genes directly implicated in INH resistance could not account for the abrogation of INH killing in nongrowing bacilli. Thus, factors affecting the requirement for mycolic acids and the redox status of bacilli are likely responsible for the reduction in INH efficacy. We speculate on additional mechanisms revealed by transcriptome analysis that might account for INH tolerance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21426023      PMCID: PMC7166126          DOI: 10.4155/fmc.10.219

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  71 in total

1.  Gene expression profile of Mycobacterium tuberculosis in a non-replicating state.

Authors:  D G Niranjala Muttucumaru; Gretta Roberts; Jason Hinds; Richard A Stabler; Tanya Parish
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

2.  Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Manzour Hernando Hazbón; Michael Brimacombe; Miriam Bobadilla del Valle; Magali Cavatore; Marta Inírida Guerrero; Mandira Varma-Basil; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Clara Inés León; Mridula Bose; Fernando Chaves; Megan Murray; Kathleen D Eisenach; José Sifuentes-Osornio; M Donald Cave; Alfredo Ponce de León; David Alland
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

4.  Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization.

Authors:  M Wilson; J DeRisi; H H Kristensen; P Imboden; S Rane; P O Brown; G K Schoolnik
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

5.  Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.

Authors:  D A Rozwarski; G A Grant; D H Barton; W R Jacobs; J C Sacchettini
Journal:  Science       Date:  1998-01-02       Impact factor: 47.728

Review 6.  Tuberculosis - metabolism and respiration in the absence of growth.

Authors:  Helena I M Boshoff; Clifton E Barry
Journal:  Nat Rev Microbiol       Date:  2005-01       Impact factor: 60.633

7.  Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: a model for persistent organisms?

Authors:  Tobias Hampshire; Shamit Soneji; Joanna Bacon; Brian W James; Jason Hinds; Ken Laing; Richard A Stabler; Philip D Marsh; Philip D Butcher
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

8.  Mycobacterium tuberculosis WhiB3 maintains redox homeostasis by regulating virulence lipid anabolism to modulate macrophage response.

Authors:  Amit Singh; David K Crossman; Deborah Mai; Loni Guidry; Martin I Voskuil; Matthew B Renfrow; Adrie J C Steyn
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

9.  Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum.

Authors:  Natalie J Garton; Simon J Waddell; Anna L Sherratt; Su-Min Lee; Rebecca J Smith; Claire Senner; Jason Hinds; Kumar Rajakumar; Richard A Adegbola; Gurdyal S Besra; Philip D Butcher; Michael R Barer
Journal:  PLoS Med       Date:  2008-04-01       Impact factor: 11.069

10.  Mycobacterium tuberculosis from chronic murine infections that grows in liquid but not on solid medium.

Authors:  Jasvir Dhillon; Douglas B Lowrie; Denis A Mitchison
Journal:  BMC Infect Dis       Date:  2004-11-17       Impact factor: 3.090

View more
  11 in total

1.  Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis.

Authors:  Nicholas D Walter; Gregory M Dolganov; Benjamin J Garcia; William Worodria; Alfred Andama; Emmanuel Musisi; Irene Ayakaka; Tran T Van; Martin I Voskuil; Bouke C de Jong; Rebecca M Davidson; Tasha E Fingerlin; Katerina Kechris; Claire Palmer; Payam Nahid; Charles L Daley; Mark Geraci; Laurence Huang; Adithya Cattamanchi; Michael Strong; Gary K Schoolnik; John Lucian Davis
Journal:  J Infect Dis       Date:  2015-03-11       Impact factor: 5.226

2.  Polyphosphate deficiency in Mycobacterium tuberculosis is associated with enhanced drug susceptibility and impaired growth in guinea pigs.

Authors:  Ramandeep Singh; Mamta Singh; Garima Arora; Santosh Kumar; Prabhakar Tiwari; Saqib Kidwai
Journal:  J Bacteriol       Date:  2013-04-12       Impact factor: 3.490

Review 3.  Mechanisms of Drug-Induced Tolerance in Mycobacterium tuberculosis.

Authors:  Sander N Goossens; Samantha L Sampson; Annelies Van Rie
Journal:  Clin Microbiol Rev       Date:  2020-10-14       Impact factor: 26.132

4.  Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters.

Authors:  Iris Keren; Shoko Minami; Eric Rubin; Kim Lewis
Journal:  MBio       Date:  2011-06-14       Impact factor: 7.867

5.  Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy.

Authors:  Isobella Honeyborne; Timothy D McHugh; Iitu Kuittinen; Anna Cichonska; Dimitrios Evangelopoulos; Katharina Ronacher; Paul D van Helden; Stephen H Gillespie; Delmiro Fernandez-Reyes; Gerhard Walzl; Juho Rousu; Philip D Butcher; Simon J Waddell
Journal:  BMC Med       Date:  2016-04-07       Impact factor: 8.775

6.  Hypoxic Non-replicating Persistent Mycobacterium tuberculosis Develops Thickened Outer Layer That Helps in Restricting Rifampicin Entry.

Authors:  Kishor Jakkala; Parthasarathi Ajitkumar
Journal:  Front Microbiol       Date:  2019-10-11       Impact factor: 5.640

Review 7.  Genome-Wide Transcriptional Responses of Mycobacterium to Antibiotics.

Authors:  Julien Briffotaux; Shengyuan Liu; Brigitte Gicquel
Journal:  Front Microbiol       Date:  2019-02-20       Impact factor: 5.640

8.  Three-dimensional low shear culture of Mycobacterium bovis BCG induces biofilm formation and antimicrobial drug tolerance.

Authors:  Daire Cantillon; Justyna Wroblewska; Ian Cooper; Melanie J Newport; Simon J Waddell
Journal:  NPJ Biofilms Microbiomes       Date:  2021-02-01       Impact factor: 7.290

9.  Antimicrobial treatment improves mycobacterial survival in nonpermissive growth conditions.

Authors:  Obolbek Turapov; Simon J Waddell; Bernard Burke; Sarah Glenn; Asel A Sarybaeva; Griselda Tudo; Gilles Labesse; Danielle I Young; Michael Young; Peter W Andrew; Philip D Butcher; Martin Cohen-Gonsaud; Galina V Mukamolova
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

10.  A class of hydrazones are active against non-replicating Mycobacterium tuberculosis.

Authors:  Shilah A Bonnett; Devon Dennison; Megan Files; Anumita Bajpai; Tanya Parish
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.